KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Income (2016 - 2025)

Teva Pharmaceutical Industries' Operating Income history spans 10 years, with the latest figure at $300.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 1134.48% year-over-year to $300.0 million, compared with a TTM value of $2.2 billion through Dec 2025, up 811.55%, and an annual FY2025 reading of $2.2 billion, up 811.88% over the prior year.
  • Operating Income for Q4 2025 was $300.0 million at Teva Pharmaceutical Industries, down from $882.0 million in the prior quarter.
  • The five-year high for Operating Income was $882.0 million in Q3 2025, with the low at -$967.0 million in Q2 2022.
  • Average Operating Income over 5 years is $90.4 million, with a median of $189.0 million recorded in 2021.
  • Year-over-year, Operating Income tumbled 1576.92% in 2024 and then skyrocketed 9200.0% in 2025.
  • Tracing TEVA's Operating Income over 5 years: stood at $78.0 million in 2021, then tumbled by 1305.13% to -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Operating Income are $300.0 million (Q4 2025), $882.0 million (Q3 2025), and $455.0 million (Q2 2025).